In The News Posted March 26, 2021 Share Posted March 26, 2021 - Patentanmeldung zur Behandlung neu auftretender SARS-CoV-2-Varianten - Nationale Phase bei Einreichungen für Krebsimpfstoff VANCOUVER, British Columbia, 26. März 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) („BioVaxys" oder „das Unternehmen"), der...View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.